Indalo Therapeutics Appoints Seasoned Biopharmaceutical Executive Robert Jacks President and CEO

Lead drug candidate IDL-2965 to enter clinical trials in early 2019 CAMBRIDGE, Mass., Jan. 28, 2019 -- (Healthcare Sales & Marketing Network) -- Indalo Therapeutics, a biopharmaceutical company discovering and developing integrin antagonists for patien... Biopharmaceuticals, Personnel Indalo Therapeutics, nonalcoholic steatohepatitis, pulmonary fibrosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news